TLSA - Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease | Benzinga
- Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer's disease (AD) and Parkinson's disease (PD)
- Nasal anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studies
- Neuroinflammation modulation may be synergistic to approved treatments in Alzheimer's Disease
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal antibody in models of Alzheimer's and Parkinson's disease at AD/PD, March 5-9, 2024. AD/PD is the annual International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Lisbon, Portugal.
Presentation Information
Presenter: Howard L Weiner, M.D.
Title: Nasal immunotherapy of the Monocyte-Microglial axis to treat Alzheimer's Disease
Day: Friday, March 8th
Time: 15:05 UTC
Location: Auditorium V
Howard L. Weiner, M.D., Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham, and Chairman of Tiziana's ...